TKI treatment breaks may not affect outcomes in kidney cancer
The results of the phase 2/3 STAR trial were published [...]
ASCO GU 2023: Further information from the cabozantinib plus nivolumab study
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
Emergency presentations: what are they, and what do they mean for cancer survival?
Cancer Research UK has written an interesting blog on the [...]
Cabozantinib after progression of kidney cancer improves survival
In a recent study, the use of cabozantinib after progression [...]
PARP1 as a potential biomarker for response to immunotherapy
In a recent study, the researchers looked at the RNA [...]
Survival after nephrectomy for various kidney cancer subtypes
Data presented at the American Urological Association (AUA) 2021 meeting [...]
Obesity and kidney cancer
A large review of the data showed that cancer specific [...]
Active surveillance for young patients with small renal masses
Active surveillance is increasingly being used for the management of [...]
Psychosocial effects of kidney cancer
As with most cancers, the psychosocial effects of renal cell [...]
The significance of body mass index (BMI) on kidney cancer outcomes
Being overweight or obese is a well-known risk factor for [...]
